Tech Transfer eNews Blog

Canada’s National Research Council licenses novel Alzheimer’s treatment to KalGene

By David Schwartz
Published: January 21st, 2015

The National Research Council of Canada (NRC) and KalGene Pharmaceuticals have entered into a licensing agreement to develop and commercialize a novel treatment for Alzheimer’s.

The NRC technology is a therapeutic molecule that targets amyloid beta plaques, or abnormal clusters of protein fragments that accumulate between brain nerve cells. These clusters are suspected to lead to the development and progression of Alzheimer’s.

To get the therapeutic past the blood-brain barrier to the site of disease, the molecule will be coupled with NRC’s carrier antibodies, which act like Trojan horses to move the molecule past the barrier and into the brain. Once inside, it binds to amyloid beta and prevents it from aggregating. Then the molecule leaves the brain, taking the harmful deposits with it.

As life expectancy rises worldwide, Alzheimer’s is becoming an increasingly devastating disease, putting an enormous strain on caregivers and healthcare systems. In Canada alone there are over 500,000 patients with dementia, and care costs are surpassing $15 billion per year.  

“We believe that NRC’s molecule, coupled with their carriers, could enable the development of a disease-modifying drug to fight Alzheimer’s,” says KalGene CEO Dr. T. Nathan Yoganathan. “We are committed to co-developing new treatments with NRC against diseases that have traditionally been difficult to treat. This license agreement brings new treatments one step closer to people living with Alzheimer’s.”

Source: Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment